Vivus Inc (VVUS) 5.24 $VVUS
Wider-than-Expected Loss at Orexigen in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:50AM CDT
Orexigen Therapeutics reported a net loss of 23 cents per share in the first quarter of 2014.
VIVUS to Present at Upcoming Investor Conference
Marketwire - Thu May 08, 3:31PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that management will present an overview of the company at the following investor conference:
Should You Worry About the Short Interest in VIVUS (VVUS)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
Should You Worry About the Short Interest in VIVUS (VVUS)?
Vivus Has Returned 36.4% Since SmarTrend Recommendation (VVUS)
Comtex SmarTrend(R) - Wed May 07, 4:39PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 4 months, Vivus has returned 36.38% as of today's recent price of $5.50.
Nasdaq stocks posting largest percentage increases
AP - Wed May 07, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
VIVUS Inc. (VVUS) in Focus: Stock Rises 7.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:44AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rally over 7% on the day.
Active Stocks at a Glance -- Research on Oi S.A., Hyperdynamics, Vivus, and EMC Corp.
PR Newswire - Wed May 07, 7:00AM CDT
The markets on Tuesday, May 06, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,401.02, down 0.78% and the NASDAQ Composite closed at 4,080.76, down 1.38%. The S&P 500 edged 0.90% lower, to finish the day at 1,867.72. The losses were broad based as nine out of ten sectors finished on a negative note. During the session losses in the Financials, Consumer Discretionary, and Information Technology ended in negative, while some positive momentum was observed in the Energy sector. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Oi S.A. (NYSE: OIBR), Hyperdynamics Corporation (NYSE: HDY), Vivus Inc. (NASDAQ: VVUS) and EMC Corporation (NYSE: EMC). Free technical research on OIBR, HDY, VVUS and EMC can be downloaded upon signing up at:
VIVUS Reports First Quarter 2014 Financial Results
Marketwire - Wed May 07, 5:24AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the first quarter ended March 31, 2014 and provided a business update.
Why VIVUS, Checkpoint Systems, and LeapFrog Enterprises Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue May 06, 7:05PM CDT
The stock market fell back on Tuesday, with a combination of factors weighing on investor sentiment. Rising tension in Ukraine added to the general anxiety level, and slowing gains in home prices made some investors believe the best of the housing...
Why VIVUS, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 12:18PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Wider-than-Expected Loss at Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:20AM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) reported first quarter 2014 loss (including stock-based compensation expense) of 47 cents per share.
VIVUS Reports Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:00AM CDT
VIVUS Inc.'s (VVUS) first quarter 2014 loss (excluding one-time items) of 13 cents per share.
Why VIVUS (VVUS) Stock is Surging Today
at The Street - Tue May 06, 9:49AM CDT
VIVUS (VVUS) rose Tuesday after the pharmaceutical company crushed analysts' estimates with its first-quarter report despite a dip in prescriptions of Qsymia, its obesity treatment drug.
VIVUS Blows Out Estimates, But For All the Wrong Reasons
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 9:03AM CDT
After the closing bell on Monday, VIVUS shares entered unchartered territory following the release of its first-quarter earnings report -- and by unchartered I mean actually up . VIVUS hasn't had the best of luck come earnings time. In fact,...
Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market 2014
M2 - Tue May 06, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mk3bhv/a_strategic) has announced the addition of the "A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market" report to their offering. Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region. Executive Summary: - The FDA recently approved 2 new prescription obesity treatments: Arena Pharmaceuticals' Belviq (partnered with Eisai) launched in June 2013, and Vivus' Qsymia, which became available September 2012. These FDA approvalsthe first for obesity in more than a decadeadd new therapeutic options to a market previously comprising a single approved drug: Roche's Xenical. - A third new drug, Orexigen's Contrave, is pending FDA approval upon successful demonstration of cardiac safety in an ongoing trial for cardiovascular outcomes and resubmission of the new drug application (NDA) in December 2013. A decision is expected from the FDA June 10, 2014, and in the second half of 2014 from the EMA. o All three of these new drugs were initially rejected by the FDA, which sought additional confirmation of an acceptable safety profile. - Approval of the obesity indication for Novo Nordisk's Victoza (liraglutide) could come as soon as mid-2014, closely coinciding with the potential approval of Contrave. - Market uptake of Qsymia and Belviq has been below expectations, largely due to insurance reimbursement hurdles and possibly because of physician and patient concerns about safety. Contrave, if approved, may have better uptake in light of its designation as an uncontrolled substance and stronger marketing capabilities of partner Takeda, particularly to the primary care and diabetes communities. - Global medical and regulatory communities recognize the urgent need for the pharmacotherapeutic treatment of obesity when lifestyle interventions fail to adequately address excess body fat. - While numerous sympathomimetic amine anorectics such as phentermine, benzphetamine, and diethylpropion are available by prescription, association with serious side effects limits their use, and prescribing is mainly limited to bariatric surgeons. - The global market potential for safe and effective obesity therapies is significant; howeverthe discovery and development of efficacious weight-loss drugs that are safe enough for - chronic use has proved challenging for even the most capable pharmaceutical and biotech companies. - Ongoing research efforts are beginning to shed new light on the pathology of obesity, as recent discoveries of differential gene expression and genetic variants found in the different fat depots advance our understanding of why abdominal fat is more strongly associated with morbidity and mortality compared with subcutaneous adipose tissue. Discoveries such as these could eventually lead to targeted therapies aimed at reducing visceral adiposity. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction to the Global Anti-obesity Prescription Drugs Market - Obesity Indication Background - Historical and Projected Timeline for Anti-obesity Drugs - Potential Prescribing Behavior Scenario - Regulators' Recommendations for Designing Anti-obesity Drug Clinical Trials - Regional Comparison of Drug Approval Requirements - Global Prevalence of Obesity by Region - Market Overview: Segmentation 4. Competitive Landscape - Anti-obesity Prescription Pharmaceuticals Market: Competitive Landscape - Ongoing Phase 3 Trials for Obesity Drugs - Ongoing Post-marketing Trials for Obesity Drugs - Comparative Efficacy of Obesity Drugs - Pivotal Trial Programs of Recently Approved Anti-obesity Drugs - Pivotal Trial Programs of Late-stage Anti-obesity Drugs - Marketed Products Synopsis - Pipeline Synopsis - Qsymia (phentermine/topiramat ER) - Belviq (lorcaserin HCl) - Contrave (bupropion SR/ naltrexone SR) - Victoza (liraglutide) 5. Conclusions and Recommendations Companies Mentioned - 7TM Pharma - Akrimax Pharmaceuticals - Aliz? Pharma - Alpex Pharma SA - Ami Pharm - Angio Lab - Arena Pharmaceuticals - Arrowhead Research - AstraZeneca - Bridge BioResearch - Boehringer Ingelheim - Compellis Pharmaceuticals - VIVUS - Yungjin Pharm - Zafgen - Zealand Pharma - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/mk..._strategic
Biotech Tweet of the Week: Do Your Due Diligence
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:25PM CDT
Our tweet of the week comes from Mandy Jackson quoting Steve Burrill at a Southern California biotech industry conference, where the venture-capital guru said that his fund looked at 150 companies last year for every one they funded. While...
VIVUS Announces Date of First Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Tue Apr 29, 6:01AM CDT
VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the first quarter ended March 31, 2014 after the NASDAQ Market closes on Monday, May 5, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.
Shares of VVUS Down 40.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 23, 9:11AM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 3 months, Vivus has returned 40.08% as of today's recent price of $5.18.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 23, 6:42AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Wider-than-Expected Loss at Orexigen in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:50AM CDT
Orexigen Therapeutics reported a net loss of 23 cents per share in the first quarter of 2014.
VIVUS to Present at Upcoming Investor Conference
Marketwire - Thu May 08, 3:31PM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced that management will present an overview of the company at the following investor conference:
Should You Worry About the Short Interest in VIVUS (VVUS)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:20AM CDT
Should You Worry About the Short Interest in VIVUS (VVUS)?
Vivus Has Returned 36.4% Since SmarTrend Recommendation (VVUS)
Comtex SmarTrend(R) - Wed May 07, 4:39PM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 4 months, Vivus has returned 36.38% as of today's recent price of $5.50.
Nasdaq stocks posting largest percentage increases
AP - Wed May 07, 12:19PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
VIVUS Inc. (VVUS) in Focus: Stock Rises 7.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:44AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rally over 7% on the day.
Active Stocks at a Glance -- Research on Oi S.A., Hyperdynamics, Vivus, and EMC Corp.
PR Newswire - Wed May 07, 7:00AM CDT
The markets on Tuesday, May 06, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,401.02, down 0.78% and the NASDAQ Composite closed at 4,080.76, down 1.38%. The S&P 500 edged 0.90% lower, to finish the day at 1,867.72. The losses were broad based as nine out of ten sectors finished on a negative note. During the session losses in the Financials, Consumer Discretionary, and Information Technology ended in negative, while some positive momentum was observed in the Energy sector. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include Oi S.A. (NYSE: OIBR), Hyperdynamics Corporation (NYSE: HDY), Vivus Inc. (NASDAQ: VVUS) and EMC Corporation (NYSE: EMC). Free technical research on OIBR, HDY, VVUS and EMC can be downloaded upon signing up at:
VIVUS Reports First Quarter 2014 Financial Results
Marketwire - Wed May 07, 5:24AM CDT
VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today reported its financial results for the first quarter ended March 31, 2014 and provided a business update.
Why VIVUS, Checkpoint Systems, and LeapFrog Enterprises Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue May 06, 7:05PM CDT
The stock market fell back on Tuesday, with a combination of factors weighing on investor sentiment. Rising tension in Ukraine added to the general anxiety level, and slowing gains in home prices made some investors believe the best of the housing...
Why VIVUS, Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 12:18PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of VIVUS , a biopharmaceutical company...
Wider-than-Expected Loss at Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:20AM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) reported first quarter 2014 loss (including stock-based compensation expense) of 47 cents per share.
VIVUS Reports Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:00AM CDT
VIVUS Inc.'s (VVUS) first quarter 2014 loss (excluding one-time items) of 13 cents per share.
Why VIVUS (VVUS) Stock is Surging Today
at The Street - Tue May 06, 9:49AM CDT
VIVUS (VVUS) rose Tuesday after the pharmaceutical company crushed analysts' estimates with its first-quarter report despite a dip in prescriptions of Qsymia, its obesity treatment drug.
VIVUS Blows Out Estimates, But For All the Wrong Reasons
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 9:03AM CDT
After the closing bell on Monday, VIVUS shares entered unchartered territory following the release of its first-quarter earnings report -- and by unchartered I mean actually up . VIVUS hasn't had the best of luck come earnings time. In fact,...
Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market 2014
M2 - Tue May 06, 3:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mk3bhv/a_strategic) has announced the addition of the "A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market" report to their offering. Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region. Executive Summary: - The FDA recently approved 2 new prescription obesity treatments: Arena Pharmaceuticals' Belviq (partnered with Eisai) launched in June 2013, and Vivus' Qsymia, which became available September 2012. These FDA approvalsthe first for obesity in more than a decadeadd new therapeutic options to a market previously comprising a single approved drug: Roche's Xenical. - A third new drug, Orexigen's Contrave, is pending FDA approval upon successful demonstration of cardiac safety in an ongoing trial for cardiovascular outcomes and resubmission of the new drug application (NDA) in December 2013. A decision is expected from the FDA June 10, 2014, and in the second half of 2014 from the EMA. o All three of these new drugs were initially rejected by the FDA, which sought additional confirmation of an acceptable safety profile. - Approval of the obesity indication for Novo Nordisk's Victoza (liraglutide) could come as soon as mid-2014, closely coinciding with the potential approval of Contrave. - Market uptake of Qsymia and Belviq has been below expectations, largely due to insurance reimbursement hurdles and possibly because of physician and patient concerns about safety. Contrave, if approved, may have better uptake in light of its designation as an uncontrolled substance and stronger marketing capabilities of partner Takeda, particularly to the primary care and diabetes communities. - Global medical and regulatory communities recognize the urgent need for the pharmacotherapeutic treatment of obesity when lifestyle interventions fail to adequately address excess body fat. - While numerous sympathomimetic amine anorectics such as phentermine, benzphetamine, and diethylpropion are available by prescription, association with serious side effects limits their use, and prescribing is mainly limited to bariatric surgeons. - The global market potential for safe and effective obesity therapies is significant; howeverthe discovery and development of efficacious weight-loss drugs that are safe enough for - chronic use has proved challenging for even the most capable pharmaceutical and biotech companies. - Ongoing research efforts are beginning to shed new light on the pathology of obesity, as recent discoveries of differential gene expression and genetic variants found in the different fat depots advance our understanding of why abdominal fat is more strongly associated with morbidity and mortality compared with subcutaneous adipose tissue. Discoveries such as these could eventually lead to targeted therapies aimed at reducing visceral adiposity. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction to the Global Anti-obesity Prescription Drugs Market - Obesity Indication Background - Historical and Projected Timeline for Anti-obesity Drugs - Potential Prescribing Behavior Scenario - Regulators' Recommendations for Designing Anti-obesity Drug Clinical Trials - Regional Comparison of Drug Approval Requirements - Global Prevalence of Obesity by Region - Market Overview: Segmentation 4. Competitive Landscape - Anti-obesity Prescription Pharmaceuticals Market: Competitive Landscape - Ongoing Phase 3 Trials for Obesity Drugs - Ongoing Post-marketing Trials for Obesity Drugs - Comparative Efficacy of Obesity Drugs - Pivotal Trial Programs of Recently Approved Anti-obesity Drugs - Pivotal Trial Programs of Late-stage Anti-obesity Drugs - Marketed Products Synopsis - Pipeline Synopsis - Qsymia (phentermine/topiramat ER) - Belviq (lorcaserin HCl) - Contrave (bupropion SR/ naltrexone SR) - Victoza (liraglutide) 5. Conclusions and Recommendations Companies Mentioned - 7TM Pharma - Akrimax Pharmaceuticals - Aliz? Pharma - Alpex Pharma SA - Ami Pharm - Angio Lab - Arena Pharmaceuticals - Arrowhead Research - AstraZeneca - Bridge BioResearch - Boehringer Ingelheim - Compellis Pharmaceuticals - VIVUS - Yungjin Pharm - Zafgen - Zealand Pharma - Zydus Cadila For more information visit http://www.researchandmarkets.com/research/mk..._strategic
Biotech Tweet of the Week: Do Your Due Diligence
Brian Orelli, The Motley Fool - Motley Fool - Mon May 05, 5:25PM CDT
Our tweet of the week comes from Mandy Jackson quoting Steve Burrill at a Southern California biotech industry conference, where the venture-capital guru said that his fund looked at 150 companies last year for every one they funded. While...
VIVUS Announces Date of First Quarter 2014 Update and Financial Results Conference Call
GlobeNewswire - Tue Apr 29, 6:01AM CDT
VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the first quarter ended March 31, 2014 after the NASDAQ Market closes on Monday, May 5, 2014. The company will conduct a conference call and an audio webcast at 4:30pm EDT the same day.
Shares of VVUS Down 40.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 23, 9:11AM CDT
SmarTrend identified a Downtrend for Vivus (NASDAQ:VVUS) on January 22nd, 2014 at $8.65. In approximately 3 months, Vivus has returned 40.08% as of today's recent price of $5.18.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Apr 23, 6:42AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
